Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Am Acad Dermatol. 2009 Mar;60(3):496-7. doi: 10.1016/j.jaad.2008.09.007.

Bortezomib-induced histiocytoid Sweet syndrome.

Author information

  • 1Department of Dermatology, University of California, San Francisco, California, USA. jemurase@gmail.com

Abstract

Bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma, has been reported to be associated with Sweet syndrome. However, careful review of the histopathology of the first reported case and our case revealed similar histologic and immunohistochemical findings (a mononuclear dermal infiltrate) and not the usual neutrophilic infiltrate of Sweet syndrome. We suggest that the dermatitis induced by bortezomib is best classified as "histiocytoid Sweet syndrome."

PMID:
19231647
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk